JP2014201577A - アレルギー性疾患の予防または治療のための医薬組成物 - Google Patents
アレルギー性疾患の予防または治療のための医薬組成物 Download PDFInfo
- Publication number
- JP2014201577A JP2014201577A JP2013081548A JP2013081548A JP2014201577A JP 2014201577 A JP2014201577 A JP 2014201577A JP 2013081548 A JP2013081548 A JP 2013081548A JP 2013081548 A JP2013081548 A JP 2013081548A JP 2014201577 A JP2014201577 A JP 2014201577A
- Authority
- JP
- Japan
- Prior art keywords
- epete
- allergic
- pharmaceutical composition
- dihete
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 230000002265 prevention Effects 0.000 title claims abstract description 10
- 210000003630 histaminocyte Anatomy 0.000 claims abstract description 38
- 239000002207 metabolite Substances 0.000 claims abstract description 13
- 208000004262 Food Hypersensitivity Diseases 0.000 claims abstract description 11
- 235000020932 food allergy Nutrition 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- XYDVGNAQQFWZEF-JPURVOHMSA-N 17,18-DiHETE Chemical compound CCC(O)C(O)C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O XYDVGNAQQFWZEF-JPURVOHMSA-N 0.000 claims abstract description 10
- 239000000651 prodrug Substances 0.000 claims abstract description 10
- 229940002612 prodrug Drugs 0.000 claims abstract description 10
- 206010016946 Food allergy Diseases 0.000 claims abstract description 7
- 239000003112 inhibitor Substances 0.000 claims abstract description 6
- GPQVVJQEBXAKBJ-JPURVOHMSA-N 17(18)-EpETE Chemical compound CCC1OC1C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O GPQVVJQEBXAKBJ-JPURVOHMSA-N 0.000 claims abstract 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 32
- 208000010668 atopic eczema Diseases 0.000 claims description 24
- 230000000172 allergic effect Effects 0.000 claims description 23
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 13
- 201000010105 allergic rhinitis Diseases 0.000 claims description 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 20
- 229960001340 histamine Drugs 0.000 abstract description 10
- 239000012453 solvate Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 19
- 230000037396 body weight Effects 0.000 description 18
- 108010058846 Ovalbumin Proteins 0.000 description 16
- 229940092253 ovalbumin Drugs 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 9
- 230000001387 anti-histamine Effects 0.000 description 9
- 239000000739 antihistaminic agent Substances 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- GPQVVJQEBXAKBJ-IXEYAUFLSA-N (5e,8e,11e,14e)-16-(3-ethyloxiran-2-yl)hexadeca-5,8,11,14-tetraenoic acid Chemical compound CCC1OC1C\C=C\C\C=C\C\C=C\C\C=C\CCCC(O)=O GPQVVJQEBXAKBJ-IXEYAUFLSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- -1 2- (N, N-diethylamino) ethyl Chemical group 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
- 102000000018 Chemokine CCL2 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101000897464 Mus musculus C-C motif chemokine 2 Proteins 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000019872 Drug Eruptions Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 208000028004 allergic respiratory disease Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 201000004335 respiratory allergy Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- YVKMMZAFUFUAAX-UHFFFAOYSA-N aluminum;tetrahydrate Chemical compound O.O.O.O.[Al] YVKMMZAFUFUAAX-UHFFFAOYSA-N 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
(1)17,18−エポキシエイコサテトラエン酸、17,18−ジヒドロキシ−エイコサ−5,8,11,14−テトラエノイン酸、これらの代謝産物若しくはこれらのプロドラッグまたはこれらの薬学的に許容可能な塩を含んでなる、医薬組成物。
(2)アレルギー性疾患の予防および/または治療のための、請求項1に記載の医薬組成物。
(3)アレルギー性疾患が、食物アレルギー、アレルギー性下痢またはアレルギー性鼻炎である、請求項2に記載の医薬組成物。
(4)17,18−エポキシエイコサテトラエン酸、17,18−ジヒドロキシ−エイコサ−5,8,11,14−テトラエノイン酸、これらの代謝産物若しくはこれらのプロドラッグまたはこれらの薬学的に許容可能な塩を含んでなる、マスト細胞の脱顆粒反応の抑制剤。
本実施例では、17,18−エポキシエイコサテトラエン酸(EpETE)および17,18−ジヒドロキシ−エイコサ−5,8,11,14−テトラエノイン酸(diHETE)がアレルギー性下痢を発症したマウスに対して及ぼす効果を検証した。
本実施例では、diHETEおよびEpETEのアレルギー性下痢に対する抑制効果の作用機序を調べた。
本実施例では、マスト細胞の脱顆粒反応に対する阻害活性を有することをさらに確認するために、インビトロで培養したマスト細胞を用いて、diHETEまたはEpETEの脱顆粒反応の阻害活性を検証した。
実施例1〜3では、下痢発症前にEpETEを投与した場合には、EpETEが下痢の発症を抑制することを明らかにした。本実施例では、下痢発症後に投与を開始した場合でもEpETEは、下痢の抑制に効果を発揮するかを調べた。
本実施例では、呼吸器系のアレルギーであるアレルギー性鼻炎に対するEpETEの効果を検証した。
Claims (4)
- 17,18−エポキシエイコサテトラエン酸、17,18−ジヒドロキシ−エイコサ−5,8,11,14−テトラエノイン酸、これらの代謝産物若しくはこれらのプロドラッグまたはこれらの薬学的に許容可能な塩を含んでなる、医薬組成物。
- アレルギー性疾患の予防および/または治療のための、請求項1に記載の医薬組成物。
- アレルギー性疾患が、食物アレルギー、アレルギー性下痢またはアレルギー性鼻炎である、請求項2に記載の医薬組成物。
- 17,18−エポキシエイコサテトラエン酸、17,18−ジヒドロキシ−エイコサ−5,8,11,14−テトラエノイン酸、これらの代謝産物若しくはこれらのプロドラッグまたはこれらの薬学的に許容可能な塩を含んでなる、マスト細胞の脱顆粒反応の抑制剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013081548A JP6153193B2 (ja) | 2013-04-09 | 2013-04-09 | アレルギー性疾患の予防または治療のための医薬組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013081548A JP6153193B2 (ja) | 2013-04-09 | 2013-04-09 | アレルギー性疾患の予防または治療のための医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014201577A true JP2014201577A (ja) | 2014-10-27 |
JP6153193B2 JP6153193B2 (ja) | 2017-06-28 |
Family
ID=52352337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013081548A Active JP6153193B2 (ja) | 2013-04-09 | 2013-04-09 | アレルギー性疾患の予防または治療のための医薬組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6153193B2 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001220355A (ja) * | 2000-02-07 | 2001-08-14 | Teijin Ltd | PPARβ/δ及びγリガンドからなる肥満細胞活性化抑制剤 |
-
2013
- 2013-04-09 JP JP2013081548A patent/JP6153193B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001220355A (ja) * | 2000-02-07 | 2001-08-14 | Teijin Ltd | PPARβ/δ及びγリガンドからなる肥満細胞活性化抑制剤 |
Non-Patent Citations (8)
Title |
---|
AM. J. RESPIR. CELL MOL. BIOL., 2010, VOL.43, NO.5, PP.564-575, JPN6017002967 * |
CLIN. DEV. IMMUNOL., 2012, VOL.2012, ART.ID 236564, JPN6017002974 * |
EUR. RESPIR. J., 2000, VOL.16, NO.5, PP.861-865, JPN6017002976 * |
J. MED. CHEM., 2011, VOL.54, NO.12, PP.4109-4118, JPN6017002965 * |
NEW FOOD INDUSTRY, 2002, VOL.44, NO.11, PP.25-32, JPN7017000338 * |
RESPIR. MED., 2010, VOL.104, NO.5, PP.668-674, JPN6017002969 * |
RESPIR. RES., 2007, VOL.8, ART.NO.90, JPN6017002971 * |
岡田 和也、他: "粘膜免疫制御による免疫疾患治療 −アレルギーからワクチンまで", 別冊・医学のあゆみ 最新免疫研究UPDATE, vol. pp.29-36, JPN7017000340, 2009 * |
Also Published As
Publication number | Publication date |
---|---|
JP6153193B2 (ja) | 2017-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5468015B2 (ja) | 抗菌ペプチド系に対する作動薬 | |
RU2607892C2 (ru) | Композиции на основе ксилита, препятствующие отделению слизи, а также смежные способы и композиции | |
US10787502B2 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
JP7161731B2 (ja) | 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用 | |
JP7097874B2 (ja) | リシルオキシダーゼ様2阻害剤の使用 | |
EP3390367B1 (en) | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation | |
EP2799071A1 (en) | Levocetirizine and montelukast for the treatment of influenza, common cold and inflammation | |
JP2018509460A (ja) | 炎症疾患及び免疫疾患を治療するための方法及び組成物 | |
JP6878596B2 (ja) | Fxrアゴニストの組合せ | |
RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
JP7229285B2 (ja) | 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法 | |
JP2020500152A5 (ja) | ||
CA2698135C (en) | Osmolytes for treating allergic or viral respiratory diseases | |
JP2016512261A (ja) | アナフィラキシーの処置におけるレボセチリジン及びモンテルカストの使用 | |
WO2021194991A1 (en) | Use of losmapimod for treatment of covid-19 | |
US11571411B2 (en) | Use of a bisamide derivative of malonic acid for treating allergic and other diseases in humans and animals | |
JP6153193B2 (ja) | アレルギー性疾患の予防または治療のための医薬組成物 | |
US20220362230A1 (en) | Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling | |
JP6051315B2 (ja) | 乾癬を処置するためのピドチモドの使用 | |
JP6058156B2 (ja) | アトピー性皮膚炎を処置するためのピドチモドの使用 | |
EP3941448A1 (en) | Use of an agent capable of inhibiting the activation of mait cells for the treatment of obesity and obesity-related disorders | |
MX2012005551A (es) | Tratamiento de infecciones microbianas. | |
WO2020223893A1 (en) | Use of gold nanoclusters in treating hypercholesterolemia or hypercholesterolemia-associated diseases | |
JP2003313127A (ja) | アレルギー性疾患治療用外用剤 | |
JP2023532915A (ja) | 傷害から細胞を保護する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160411 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170404 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170509 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170525 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6153193 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |